Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Change in Account Payables (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of Change in Account Payables data on record, last reported at -$1.4 million in Q4 2025.

  • For Q4 2025, Change in Account Payables fell 1308.04% year-over-year to -$1.4 million; the TTM value through Dec 2025 reached -$887000.0, down 178.93%, while the annual FY2025 figure was -$887000.0, 178.93% down from the prior year.
  • Change in Account Payables reached -$1.4 million in Q4 2025 per OCUL's latest filing, down from -$1.3 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $1.7 million in Q2 2025 and bottomed at -$2.4 million in Q2 2024.
  • Average Change in Account Payables over 5 years is $27650.0, with a median of $211000.0 recorded in 2021.
  • Peak YoY movement for Change in Account Payables: soared 745.34% in 2021, then tumbled 1308.04% in 2025.
  • A 5-year view of Change in Account Payables shows it stood at $366000.0 in 2021, then tumbled by 406.56% to -$1.1 million in 2022, then surged by 158.47% to $656000.0 in 2023, then crashed by 82.93% to $112000.0 in 2024, then crashed by 1308.04% to -$1.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were -$1.4 million in Q4 2025, -$1.3 million in Q3 2025, and $1.7 million in Q2 2025.